First Eagle Investment Management, LLC Ironwood Pharmaceuticals Inc Transaction History

First Eagle Investment Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$5.58 - $8.61 $569,160 - $878,220	102,000 Added 10.18%	1,104,225 $7.2 Million
Q1 2024 May 09, 2024	BUY	$8.32 - $15.45 $790,400 - $1.47 Million	95,000 Added 10.47%	1,002,225 $8.73 Million
Q4 2023 Feb 08, 2024	BUY	$8.79 - $11.51 $796,690 - $1.04 Million	90,636 Added 11.1%	907,225 $10.4 Million
Q3 2023 Nov 08, 2023	BUY	$8.25 - $11.35 $1.87 Million - $2.57 Million	226,700 Added 38.43%	816,589 $7.86 Million
Q2 2023 Aug 09, 2023	BUY	$10.1 - $11.6 $995,102 - $1.14 Million	98,525 Added 20.05%	589,889 $6.28 Million
Q1 2023 May 11, 2023	BUY	$10.37 - $12.56 $1.56 Million - $1.89 Million	150,834 Added 44.29%	491,364 $5.17 Million
Q4 2022 Feb 09, 2023	BUY	$9.9 - $12.43 $841,797 - $1.06 Million	85,030 Added 33.28%	340,530 $4.22 Million
Q3 2022 Nov 10, 2022	BUY	$10.14 - $12.38 $2.59 Million - $3.16 Million	255,500 New	255,500 $2.65 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of First Eagle Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on First Eagle Investment Management, LLC with notifications on news.